Imexpharm Corporation (HOSE:IMP)

Market Cap	8.32T +21.8%
Revenue (ttm)	2.44T +10.7%
Net Income	304.39B +8.8%
EPS	1,976.44 +2.3%
Shares Out	154.01M
PE Ratio	27.32
Forward PE	22.65
Dividend	500.00 (0.92%)
Ex-Dividend Date	Jun 9, 2025

Volume	11,418
Average Volume	47,678
Open	53,700
Previous Close	54,100
Day's Range	53,700 - 54,100
52-Week Range	36,100 - 56,500
Beta	0.69
RSI	63.42
Earnings Date	Jan 16, 2026

About Imexpharm

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company’s products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. The company was founded in 1997 and is headquartered in Cao Lãnh, Vietnam.

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 1,456
• Stock Exchange: Ho Chi Minh Stock Exchange
• Ticker Symbol: IMP

Financial Performance

In 2025, Imexpharm's revenue was 2.44 trillion, an increase of 10.70% compared to the previous year's 2.21 trillion. Earnings were 304.39 billion, an increase of 2.30%.